Topical or oral? Choosing between pills and lotions according to your case.

Traditionally, finasteride is taken orally (1 mg daily) to halt hair loss and promote regrowth. Recently, topical formulations of finasteride have gained attention. Supporters hope they work as well as tablets with fewer side effects; the second point has not been established.

Regulatory status and safety. In the US there is no FDA-approved topical finasteride. Products are compounded, and the FDA has not evaluated their safety, effectiveness or quality; in April 2025 it issued a safety alert about them. A topical finasteride spray is authorised in some European countries.

Finasteride tablets carry warnings that go beyond sexual side effects. The US label lists reports of sexual problems (libido, erection, ejaculation and orgasm problems) that continued after men stopped the drug, and also depression and suicidal thoughts, breast tenderness or enlargement, reduced semen quality or infertility (reported to improve after stopping), testicular pain, allergic reactions and male breast cancer; these are post-marketing reports, not rates. Some former users also report anxiety and cognitive complaints ("brain fog"); in one small study such men had more cognitive complaints but normal results on objective tests (Basaria et al., 2016). The one-year registration trials recorded sexual side effects only, on treatment, so they cannot answer questions about mood, cognition or what happens after stopping. For the full picture see "Is finasteride safe?". The UK medicines regulator (MHRA, May 2026) states that finasteride is associated with depression, suicidal thoughts and sexual dysfunction "which may persist after treatment is stopped". In 2025 the European Medicines Agency confirmed suicidal thoughts as a side effect of finasteride tablets, with a frequency that cannot be estimated; it found no link for the skin spray. These reports come from voluntary reporting, so they cannot show how often lasting problems happen, or prove that finasteride caused them in a given person. The UK regulator (MHRA, May 2026) advises stopping finasteride 1 mg immediately and contacting a doctor if depression or suicidal thoughts develop. If you have thoughts of harming yourself, seek emergency help right away.

Finasteride in any form must not be used by women who are or may become pregnant (see the pregnancy note below).

This report provides a comprehensive review of the efficacy and differences between topical and oral finasteride, drawing on clinical studies (human trials), mechanistic research (including animal studies), meta-analyses, and reported outcomes. We examine how each route affects hair growth, DHT levels, pharmacokinetics, dosing, and side effects.

Mechanism of Action and Evidence from Research: Finasteride’s Mechanism:

Finasteride selectively inhibits 5α-reductase type II (and to a lesser extent type I), the enzyme that converts testosterone to DHT. In androgenetic alopecia, hair follicles in the scalp miniaturize under the influence of DHT. By lowering DHT, finasteride helps prevent follicular miniaturization and can restore healthier hair growth. Mechanistically, oral and topical finasteride work the same way at the hair follicle level – the difference is in drug delivery (systemic vs localized). Topical application is intended to concentrate the drug in the scalp to reduce local DHT production with less systemic absorption.

Human Mechanistic Studies: Key pharmacologic studies in humans have compared how topical vs oral finasteride affect hormone levels. In a 2014 open-label, exploratory study (Caserini et al.), 24 men with androgenetic alopecia were given either a finasteride 0.25% topical solution applied twice daily or 1 mg oral finasteride once daily for one week. Plasma DHT fell by about 68–75% with the topical solution and about 62–72% with the tablet, although blood finasteride levels were much lower with the topical. There were no relevant changes in plasma testosterone with either route. Scalp DHT was not measured. Overall, mechanistic studies (in humans and animals) support that finasteride's hair-growth effect comes from DHT blockade; this short study found that topical use still lowered DHT in the blood about as much as the tablet.

Efficacy of Oral Finasteride (Clinical Studies)

Oral finasteride (1 mg daily) is a well-established treatment for male androgenetic alopecia. Multiple large randomized controlled trials (RCTs) and long-term studies have confirmed its efficacy. In these trials, oral finasteride consistently increases hair counts and slows hair loss compared to placebo. For example, men taking 1 mg finasteride daily experienced progressive increases in hair count at 6, 12, and 24 months, whereas placebo-treated men continued to lose hair.

A network meta-analysis of treatments found that at 48 weeks, oral finasteride 1 mg/day yielded one of the greatest increases in total hair count among all hair loss therapies tested. In the registration trials, by hair count, 86% of men on finasteride had no further hair loss at 1 year, versus 42% on placebo. In one 2-year study, 83% of men on finasteride had no progression of hair loss (or improvement) versus 28% of men on placebo. In these trials, most men on finasteride had no further hair loss, and some had visible regrowth. Moreover, benefit persists with continued use: in the 5-year extension studies, average hair counts in men who stayed on the medication peaked within 2 years and then declined slowly but stayed above baseline (35% had lost hair by count at 5 years, and only 15 men remained on placebo by then), whereas those who stop tend to regress and lose hair again, reflecting DHT’s ongoing role in hair follicle miniaturization.

Note: Finasteride is sometimes prescribed off-label for women with androgenetic alopecia, by specialists; it is not approved for women, and the US label reports that a trial in 137 postmenopausal women did not show effectiveness. While this review focuses on male AGA, many findings apply broadly.

Pregnancy and transfer warning: Finasteride, oral or topical, is contraindicated in women who are or may become pregnant, because it can cause abnormalities of the genitals in a male foetus. The US label states that women who are or may be pregnant should not handle crushed or broken tablets. The FDA (2025) warns that applied topical finasteride can transfer to other people, especially women, and that compounded topical products have no protective coating. Ask the prescriber how to avoid exposing others.

Efficacy of Topical Finasteride:

Early Trials:

The first human study on topical finasteride was published in 1997 by Mazzarella. In that single-blind placebo-controlled trial, 52 patients (28 men, 24 women) applied a 0.005% finasteride solution daily for 16 months. The low-strength topical finasteride still produced improvements: it slowed hair loss and modestly increased hair growth compared to placebo, suggesting, in a small single-blind study, that even a small amount of finasteride applied to the scalp might affect androgenetic alopecia.

By the end of the study, the finasteride group showed a reduction in balding progression, whereas the placebo group had continued hair thinning; a study this small could only suggest potential.

Several other studies have evaluated topical finasteride, often in combination with minoxidil: A 2020 trial by Rossi reported that a combo of 0.25% finasteride + 5% minoxidil solution outperformed minoxidil alone in promoting hair growth. In that study only the combination showed a statistically significant increase in hair density from baseline at 6 months, whereas minoxidil by itself did not; that is not the same as a direct, significant difference between the two groups. Another study from 2021, assessed patient-reported outcomes in men using either topical finasteride with minoxidil vs oral finasteride with minoxidil.

The study reported that both approaches were well tolerated, with no patient-observed superiority of one over the other; this does not show the two are equally effective or equally safe. Most of these studies are small or short; the largest, a 24-week trial funded by the manufacturer (Piraccini 2022), is described below.

Effects on Serum DHT:

Lower systemic absorption translates to a smaller impact on serum (circulating) DHT levels for topical finasteride. Oral finasteride 1 mg typically reduces serum DHT by ~60–70% on average with daily use. Topical finasteride, in contrast, tends to cause a more modest serum DHT reduction, although still significant. In the 24-week phase III trial (Piraccini et al., 2022; 458 men), mean serum DHT dropped about 34.5% from baseline in the topical group, compared with about 55.6% in the trial's oral finasteride group. Topical finasteride increased hair counts more than placebo and by a similar amount to tablets; the trial was not designed to prove the two are equal. Adverse events did not differ meaningfully from placebo over 24 weeks, a period too short to study effects that persist after stopping. Other studies have similarly noted that topical finasteride lowers serum DHT less than oral finasteride does. Lower DHT suppression has not been shown to mean fewer side effects in practice.

However, some topical regimens can still suppress DHT considerably. Caserini et al. found that after one week of 0.25% topical finasteride applied twice daily, plasma DHT fell by about 68–75%, similar to the tablet in that short comparison.

Dosing:

There is no established conversion between tablet and topical doses. Strength and schedule are set by the prescriber and the specific product.

Anecdotal Reports from the Community

Beyond formal studies and case reports, a wealth of anecdotal information exists in online communities. One such community is Reddit’s r/tressless, the largest hair loss forum, where thousands of individuals share experiences with treatments like finasteride. These anecdotal reports are not scientific data, but they provide insights into real-world usage and perceptions of topical vs oral finasteride. Below, we summarize common themes from the Tressless community, clearly marking them as anecdotal (community experiences rather than verified research). Keep in mind individual experiences vary widely, and anecdotal reports may be subject to placebo effects, nocebo effects, and personal bias.

*Effectiveness Perceptions: Many users on Tressless who have tried topical finasteride report positive results in terms of halting hair loss and regrowth, similar to their experiences (or others’ experiences) with oral finasteride. It’s commonly stated that topical finasteride “works” for maintaining hair. For example, one user emphatically noted they had “experienced absolutely 0 side effects, not even topical ones, and am extremely happy” with their results on topical finasteride

Side Effect Comparisons:** A frequent discussion topic is whether topical finasteride truly has fewer side effects than oral. The general community consensus is that topical has a lower risk, but not zero. Many report no sexual side effects on topical, even some who had issues on oral. However, others caution that topical finasteride can still cause systemic absorption. One commenter pointed out that topical finasteride’s systemic absorption is proven to be lower than oral, but “even the reduced absorption can cause side effects” for very sensitive individuals.

Reports of Side Effects on Topical: While most seem to tolerate topical well, a few anecdotal posts describe side effects. These range from mild sexual symptoms to severe. On the extreme end, at least one user claimed to develop “full blown post-finasteride syndrome” from using topical finasteride. This individual took 0.1% topical finasteride for only 10 days and reported lasting sexual dysfunction and other issues (an anecdote that resembles reports of persistent symptoms with oral finasteride).

The FDA (2025) received 32 reports of adverse events with compounded topical finasteride between 2019 and 2024, including erectile dysfunction, decreased libido, depression, anxiety, suicidal thoughts, "brain fog", fatigue, insomnia and testicular pain; most said symptoms continued after stopping. Reports like these cannot show how often this happens, but topical use is not free of this risk. Other users have mentioned experiencing shedding or irritation with topical, or subtle decreases in libido that resolved after discontinuation (all self-reported, without medical confirmation). Many other users report no noticeable side effects on topical finasteride.

Switching from Oral to Topical: A common scenario discussed is men switching to topical finasteride after experiencing side effects on oral finasteride. Many of these users report that their side effects (for example, erectile dysfunction or low libido) went away after switching to topical, yet their hair maintenance continued. Others report that side effects continued, or that hair results were not as good as on oral. This has not been studied. Anyone with side effects should speak to their prescriber before changing treatment. The UK regulator (MHRA, May 2026) advises stopping finasteride 1 mg immediately and contacting a doctor if depression or suicidal thoughts develop.

Community Attitudes: On Tressless, there’s a mix of attitudes. Some members are very pro-topical, calling it “the perfect hair treatment no one talks about,” and wondering why more people don’t start with topical given its *“little to no side effects in comparison”. Others are more skeptical, feeling that oral is easier and the side effect difference might be overstated. There are also practical discussions about cost (topical finasteride is not mass-market in some countries and often must be compounded, which can be more expensive than generic finasteride pills). Convenience is another factor – taking a pill vs applying a topical solution daily (which can leave residue or be time-consuming). Some users find the topical routine easy, while others dislike it.

Note: Community reports are anecdotal and not rigorously verified; they should not replace clinical evidence, but rather illustrate how findings might translate to everyday use. Always consult a healthcare professional for personal medical advice.

Conclusion

In one 24-week trial, topical finasteride increased hair counts more than placebo and by a similar amount to tablets, with much lower blood levels of the drug. Whether it causes fewer side effects in practice is not established. Oral finasteride has a longer record of trial data; it lowers DHT throughout the body, and its labels warn of sexual side effects, depression and suicidal thoughts, and breast and semen changes, with reports of sexual problems that continued after stopping; some former users also report anxiety and cognitive complaints (see the safety note above).

However, it’s important to keep expectations realistic. Topical finasteride is not entirely without risk, and oral finasteride is not intolerable for everyone: in the one-year registration trials, 3.8% of men taking it reported a sexual side effect, compared with 2.1% on placebo, and those trials did not follow men after stopping. The choice between topical and oral may come down to individual preference, tolerability, cost, and access. Some may start with oral finasteride and switch to topical if needed; others might prefer to try topical first.  From a physician’s perspective, topical finasteride expands the toolkit for treating hair loss. It can be especially useful in patients who are hesitant about oral medication or who have contraindications (for example, men who are trying to conceive might prefer to avoid systemic drug exposure, since the US label lists reports of reduced semen quality or infertility, with improvement reported after stopping, and in the trials ejaculate volume fell slightly, by about 0.3 mL versus 0.2 mL on placebo at 48 weeks). Finasteride in any form is contraindicated in pregnancy (see the pregnancy note above).

Sources:

A novel finasteride 0.25% topical solution for androgenetic alopecia. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov/25074865/

Finasteride and dutasteride for the treatment of male androgenetic alopecia: A review of efficacy and reproductive adverse effects. (n.d.). GMR Scholastica. https://gmr.scholasticahq.com/article/88531

Diani, A.R., et al. (1992). Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque (animal study). Journal of Clinical Endocrinology and Metabolism, 74(2), 345-350. https://pubmed.ncbi.nlm.nih.gov/1309834/

Maculopapular drug eruption caused by finasteride: A case report. (n.d.). National Center for Biotechnology Information (NCBI). https://pmc.ncbi.nlm.nih.gov/articles/PMC10661891/

Piraccini, B.M., Blume-Peytavi, U., et al. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 36(2), 286-294. https://pubmed.ncbi.nlm.nih.gov/34634163/

Gupta, A.K., et al. (2022). Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.14895

Topical finasteride: To use or not to use? (n.d.). International Society of Hair Restoration Surgery (ISHRS). https://www.ishrs-htforum.org/content/28/3/112

US Food and Drug Administration. (2025, April 22). FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded

Organon. PROPECIA (finasteride) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36

Basaria S, Jasuja R, et al. (2016). Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss. Journal of Clinical Endocrinology and Metabolism, 101(12), 4669-4680. PMID 27662439. https://pubmed.ncbi.nlm.nih.gov/27662439/

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction. Drug Safety Update. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction

European Medicines Agency. (2025). Finasteride- and dutasteride-containing medicinal products: Article 31 referral. https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products